Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245500 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 336
- Enrollment target
- 20
- Study locations
NCT05245500: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Bristol-Myers Squibb.
NCT05245500 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 336 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05245500, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 336 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Conditions Studied
Interventions
- DRUG MRTX1719
Study Locations (20)
New York
- Local Institution - 129 - Mineola
- David H Koch, Memorial Sloan Kettering Cancer Center - New York
- New york cancer and blood specialists - Oncology - Port Jefferson Station
- New york cancer and blood specialists - Oncology - Port Jefferson Station
Texas
- Ut Southwestern - Dallas
- Texas Oncology - DFW - Fort Worth
- MDACC - Houston
Colorado
- Sarah Cannon Research Institute (SCRI) - HealthONE Location - Denver
- Rocky Mountain Cancer Centers, LLP - Oncology - Lone Tree
Florida
- Mayo Clinic - Jacksonville
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
North Carolina
- University of North Carolina - Gastroenterology and Hepatology - Chapel Hill
- University of North Carolina - Chapel Hill
Arizona
- Mayo Clinic - Phoenix
Illinois
- Local Institution - 124 - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Brookline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2027-12-10 |
| Phase | Phase 1 |
What NCT05245500 shows while recruiting
NCT05245500 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (48% lower).
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRTX1719 is the first listed.
NCT05245500 names 20 study sites across 12 states, led by New York, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT05245500 about?
NCT05245500 is a clinical study titled "Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion". This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
What is the current status of trial NCT05245500?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2022-06-09. Estimated completion is 2027-12-10.
What conditions does trial NCT05245500 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Advanced Solid Tumor, Pancreatic Adenocarcinoma, Mesothelioma.
What interventions are being tested in trial NCT05245500?
The interventions under investigation include: MRTX1719 (DRUG).
Who is sponsoring clinical trial NCT05245500?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245500 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05245500's enrollment target sits among peer trials
336 112th of 454 higher than 343 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI